Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Systematic Review Article

磷脂酰肌醇3-激酶抑制剂对乳腺癌患者的疗效和安全性:随机对照试验的系统评价和meta分析

卷 24, 期 9, 2024

发表于: 24 January, 2024

页: [941 - 951] 页: 11

弟呕挨: 10.2174/0115680096266181231207110048

价格: $65

conference banner
摘要

背景：磷脂酰肌醇3-激酶(PI3K)抑制剂属于抑制PI3K蛋白活性的一类药物，PI3K蛋白在乳腺癌细胞中通常过表达。然而，有必要总结证据，为乳腺癌患者使用PI3K抑制剂的益处提供结论性建议。因此，本综述评估了PI3K抑制剂在乳腺癌患者中的有效性和安全性。 方法：检索在PubMed Central、EMBASE、MEDLINE、SCOPUS、Central、WHO试验注册和Clinicaltrials.gov中进行，截止到2022年12月。采用随机效应模型进行meta分析。合并风险比(HR)/风险比(RR)以95%置信区间(ci)报告。 结果：总共有13项研究被纳入分析。大多数是多国研究，有较高的偏倚风险。在疗效参数方面，无进展生存期的合并危险度为0.79 (95%CI: 0.67-0.92)，完全缓解的合并危险度为1.54 [95%CI: 1.14 - 2.09]，部分缓解的合并危险度为1.18 [95%CI: 0.87-1.61]，总缓解的合并危险度为1.20 [95%CI: 0.93-1.56]，病情稳定的合并危险度为1.09 [95%CI: 0.78-1.53]，病情进展的合并危险度为0.80 [95%CI: 0.74 - 0.87]，临床获益为1.08 [95%CI: 0.80-1.49]。对于安全性参数，高血糖的合并RR为4.57 [95%CI: 3.15-6.62]，胃肠道毒性的合并RR为1.82 [95%CI: 1.56 - 2.14]。 结论：对于乳腺癌患者，尤其是PIK3CA突变患者，PI3K抑制剂的疗效优于目前关注的标准。因此，临床医生和肿瘤学家可以为目标人群提供这种药物，但对糖尿病患者要格外小心。

关键词: 乳腺癌，荟萃分析，磷脂酰肌醇3激酶抑制剂，系统评价，总生存期，无进展生存期。

« Previous Next »
图形摘要

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
National Cancer Institute. Breast Cancer Risk and Prevention., 2021. Available from: https://www.cancer.gov/types/breast/risk/prevention (Accessed on: on 3 December 2022).
[3]
American Cancer Society. Breast Cancer Treatment (PDQ®)–Patient Version. 2020. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8793.00.pdf (Accessed on: 3 December 2022).
[4]
Ellis, H.; Ma, C.X. PI3K inhibitors in breast cancer therapy. Curr. Oncol. Rep., 2019, 21(12), 110.
[http://dx.doi.org/10.1007/s11912-019-0846-7] [PMID: 31828441]
[5]
Narayan, P.; Prowell, T.M.; Gao, J.J.; Fernandes, L.L.; Li, E.; Jiang, X.; Qiu, J.; Fan, J.; Song, P.; Yu, J.; Zhang, X.; King-Kallimanis, B.L.; Chen, W.; Ricks, T.K.; Gong, Y.; Wang, X.; Windsor, K.; Rhieu, S.Y.; Geiser, G.; Banerjee, A.; Chen, X.; Reyes Turcu, F.; Chatterjee, D.K.; Pathak, A.; Seidman, J.; Ghosh, S.; Philip, R.; Goldberg, K.B.; Kluetz, P.G.; Tang, S.; Amiri-Kordestani, L.; Theoret, M.R.; Pazdur, R.; Beaver, J.A. FDA approval summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin. Cancer Res., 2021, 27(7), 1842-1849.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-3652] [PMID: 33168657]
[6]
Di Leo, A.; Johnston, S.; Lee, K.S.; Ciruelos, E.; Lønning, P.E.; Janni, W.; O’Regan, R.; Mouret-Reynier, M.A.; Kalev, D.; Egle, D.; Csőszi, T.; Bordonaro, R.; Decker, T.; Tjan-Heijnen, V.C.G.; Blau, S.; Schirone, A.; Weber, D.; El-Hashimy, M.; Dharan, B.; Sellami, D.; Bachelot, T. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 2018, 19(1), 87-100.
[http://dx.doi.org/10.1016/S1470-2045(17)30688-5] [PMID: 29223745]
[7]
Johnson, J.; Chow, Z.; Napier, D.; Lee, E.; Weiss, H.L.; Evers, B.M.; Rychahou, P. Targeting PI3K and AMPKα signaling alone or in combination to enhance radiosensitivity of triple negative breast cancer. Cells, 2020, 9(5), 1253.
[http://dx.doi.org/10.3390/cells9051253] [PMID: 32438621]
[8]
Kaboli, P.J.; Imani, S.; Jomhori, M.; Ling, K.H. Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy. Am. J. Cancer Res., 2021, 11(10), 5155-5183.
[PMID: 34765318]
[9]
Raphael, J.; Desautels, D.; Pritchard, K.I.; Petkova, E.; Shah, P.S. Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. Eur. J. Cancer, 2018, 91, 38-46.
[http://dx.doi.org/10.1016/j.ejca.2017.12.010] [PMID: 29331750]
[10]
Luo, Q.; Lu, H.; Zhou, X.; Wang, Y. The efficacy and safety of neoadjuvant buparlisib for breast cancer. Medicine, 2019, 98(44), e17614.
[http://dx.doi.org/10.1097/MD.0000000000017614] [PMID: 31689768]
[11]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Moher, D. Updating guidance for reporting systematic reviews: Development of the PRISMA 2020 statement. J. Clin. Epidemiol., 2021, 134, 103-112.
[http://dx.doi.org/10.1016/j.jclinepi.2021.02.003] [PMID: 33577987]
[12]
Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; Emberson, J.R.; Hernán, M.A.; Hopewell, S.; Hróbjartsson, A.; Junqueira, D.R.; Jüni, P.; Kirkham, J.J.; Lasserson, T.; Li, T.; McAleenan, A.; Reeves, B.C.; Shepperd, S.; Shrier, I.; Stewart, L.A.; Tilling, K.; White, I.R.; Whiting, P.F.; Higgins, J.P.T. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366, l4898.
[http://dx.doi.org/10.1136/bmj.l4898] [PMID: 31462531]
[13]
Cochrane handbook for systematic reviews of interventions; Higgins, J.P.; Green, S., Eds.; John Wiley & Sons, 2011.
[14]
Mayer, I.A.; Prat, A.; Egle, D.; Blau, S.; Fidalgo, J.A.P.; Gnant, M.; Fasching, P.A.; Colleoni, M.; Wolff, A.C.; Winer, E.P.; Singer, C.F.; Hurvitz, S.; Estévez, L.G.; van Dam, P.A.; Kümmel, S.; Mundhenke, C.; Holmes, F.; Babbar, N.; Charbonnier, L.; Diaz-Padilla, I.; Vogl, F.D.; Sellami, D.; Arteaga, C.L. A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NEO-ORB). Clin. Cancer Res., 2019, 25(10), 2975-2987.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-3160] [PMID: 30723140]
[15]
Martín, M.; Chan, A.; Dirix, L.; O’Shaughnessy, J.; Hegg, R.; Manikhas, A.; Shtivelband, M.; Krivorotko, P.; Batista López, N.; Campone, M.; Ruiz Borrego, M.; Khan, Q.J.; Beck, J.T.; Ramos Vázquez, M.; Urban, P.; Goteti, S.; Di Tomaso, E.; Massacesi, C.; Delaloge, S. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4). Ann. Oncol., 2017, 28(2), 313-320.
[http://dx.doi.org/10.1093/annonc/mdw562] [PMID: 27803006]
[16]
André, F.; Ciruelos, E.; Rubovszky, G.; Campone, M.; Loibl, S.; Rugo, H.S.; Iwata, H.; Conte, P.; Mayer, I.A.; Kaufman, B.; Yamashita, T.; Lu, Y.S.; Inoue, K.; Takahashi, M.; Pápai, Z.; Longin, A.S.; Mills, D.; Wilke, C.; Hirawat, S.; Juric, D. Alpelisib for PIK3CA -mutated, hormone receptor–positive advanced breast cancer. N. Engl. J. Med., 2019, 380(20), 1929-1940.
[http://dx.doi.org/10.1056/NEJMoa1813904] [PMID: 31091374]
[17]
Baselga, J.; Im, S.A.; Iwata, H.; Cortés, J.; De Laurentiis, M.; Jiang, Z.; Arteaga, C.L.; Jonat, W.; Clemons, M.; Ito, Y.; Awada, A.; Chia, S.; Jagiełło-Gruszfeld, A.; Pistilli, B.; Tseng, L.M.; Hurvitz, S.; Masuda, N.; Takahashi, M.; Vuylsteke, P.; Hachemi, S.; Dharan, B.; Di Tomaso, E.; Urban, P.; Massacesi, C.; Campone, M. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 2017, 18(7), 904-916.
[http://dx.doi.org/10.1016/S1470-2045(17)30376-5] [PMID: 28576675]
[18]
Oliveira, M.; Baird, R.D.; Voorthuis, R.A.B.; De Boo, L.; van Rossum, A.G.J.; Garrigos, C.L.; Muñoz, S.; López-García, D.; Saura Manich, C.; Schrier, M.; Mandjes, I.; Sikorska, K.; Schot, M.; Kateb, A.; Mather, C.; Beelen, K.; Cortés, J.; Caldas, C.; Linn, S.C. LBA18 POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC). Ann. Oncol., 2021, 32, S1291-S1292.
[http://dx.doi.org/10.1016/j.annonc.2021.08.2091]
[19]
Vuylsteke, P.; Huizing, M.; Petrakova, K.; Roylance, R.; Laing, R.; Chan, S.; Abell, F.; Gendreau, S.; Rooney, I.; Apt, D.; Zhou, J.; Singel, S.; Fehrenbacher, L. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: Interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Ann. Oncol., 2016, 27(11), 2059-2066.
[http://dx.doi.org/10.1093/annonc/mdw320] [PMID: 27573562]
[20]
Loibl, S.; de la Pena, L.; Nekljudova, V.; Zardavas, D.; Michiels, S.; Denkert, C.; Rezai, M.; Bermejo, B.; Untch, M.; Lee, S.C.; Turri, S.; Urban, P.; Kümmel, S.; Steger, G.; Gombos, A.; Lux, M.; Piccart, M.J.; Von Minckwitz, G.; Baselga, J.; Loi, S. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). Eur. J. Cancer, 2017, 85, 133-145.
[http://dx.doi.org/10.1016/j.ejca.2017.08.020] [PMID: 28923573]
[21]
Saura, C.; Hlauschek, D.; Oliveira, M.; Zardavas, D.; Jallitsch-Halper, A.; de la Peña, L.; Nuciforo, P.; Ballestrero, A.; Dubsky, P.; Lombard, J.M.; Vuylsteke, P.; Castaneda, C.A.; Colleoni, M.; Santos, B.G.; Ciruelos, E.; Fornier, M.; Boer, K.; Bardia, A.; Wilson, T.R.; Stout, T.J.; Hsu, J.Y.; Shi, Y.; Piccart, M.; Gnant, M.; Baselga, J.; de Azambuja, E. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol., 2019, 20(9), 1226-1238.
[http://dx.doi.org/10.1016/S1470-2045(19)30334-1] [PMID: 31402321]
[22]
Schmid, P.; Pinder, S.E.; Wheatley, D.; Macaskill, J.; Zammit, C.; Hu, J.; Price, R.; Bundred, N.; Hadad, S.; Shia, A.; Sarker, S.J.; Lim, L.; Gazinska, P.; Woodman, N.; Korbie, D.; Trau, M.; Mainwaring, P.; Gendreau, S.; Lackner, M.R.; Derynck, M.; Wilson, T.R.; Butler, H.; Earl, G.; Parker, P.; Purushotham, A.; Thompson, A. Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor–positive breast cancer. J. Clin. Oncol., 2016, 34(17), 1987-1994.
[http://dx.doi.org/10.1200/JCO.2015.63.9179] [PMID: 26976426]
[23]
Dent, S.; Cortés, J.; Im, Y.H.; Diéras, V.; Harbeck, N.; Krop, I.E.; Wilson, T.R.; Cui, N.; Schimmoller, F.; Hsu, J.Y.; He, J.; De Laurentiis, M.; Sousa, S.; Drullinsky, P.; Jacot, W. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: The SANDPIPER trial. Ann. Oncol., 2021, 32(2), 197-207.
[http://dx.doi.org/10.1016/j.annonc.2020.10.596] [PMID: 33186740]
[24]
Krop, I.E.; Mayer, I.A.; Ganju, V.; Dickler, M.; Johnston, S.; Morales, S.; Yardley, D.A.; Melichar, B.; Forero-Torres, A.; Lee, S.C.; de Boer, R.; Petrakova, K.; Vallentin, S.; Perez, E.A.; Piccart, M.; Ellis, M.; Winer, E.; Gendreau, S.; Derynck, M.; Lackner, M.; Levy, G.; Qiu, J.; He, J.; Schmid, P. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol., 2016, 17(6), 811-821.
[http://dx.doi.org/10.1016/S1470-2045(16)00106-6] [PMID: 27155741]
[25]
Lehmann, B.D.; Abramson, V.G.; Sanders, M.E.; Mayer, E.L.; Haddad, T.C.; Nanda, R.; Van Poznak, C.; Storniolo, A.M.; Nangia, J.R.; Gonzalez-Ericsson, P.I.; Sanchez, V.; Johnson, K.N.; Abramson, R.G.; Chen, S.C.; Shyr, Y.; Arteaga, C.L.; Wolff, A.C.; Pietenpol, J.A. TBCRC 032 IB/II multicenter study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer. Clin. Cancer Res., 2020, 26(9), 2111-2123.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-2170] [PMID: 31822498]
[26]
Costa, R.L.B.; Han, H.S.; Gradishar, W.J. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review. Breast Cancer Res. Treat., 2018, 169(3), 397-406.
[http://dx.doi.org/10.1007/s10549-018-4697-y] [PMID: 29417298]
[27]
Khan, M.A.; Jain, V.K.; Rizwanullah, M.; Ahmad, J.; Jain, K. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: A review on drug discovery and future challenges. Drug Discov. Today, 2019, 24(11), 2181-2191.
[http://dx.doi.org/10.1016/j.drudis.2019.09.001] [PMID: 31520748]
[28]
Fuso, P.; Muratore, M.; D’Angelo, T.; Paris, I.; Carbognin, L.; Tiberi, G.; Pavese, F.; Duranti, S.; Orlandi, A.; Tortora, G.; Scambia, G.; Fabi, A. PI3K inhibitors in advanced breast cancer: The past, the present, new challenges and future perspectives. Cancers, 2022, 14(9), 2161.
[http://dx.doi.org/10.3390/cancers14092161] [PMID: 35565291]
[29]
Fruman, D.A.; Rommel, C. PI3K and cancer: Lessons, challenges and opportunities. Nat. Rev. Drug Discov., 2014, 13(2), 140-156.
[http://dx.doi.org/10.1038/nrd4204] [PMID: 24481312]
[30]
Khan, K.H.; Wong, M.; Rihawi, K.; Bodla, S.; Morganstein, D.; Banerji, U.; Molife, L.R. Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: Incidence, predictive factors, and management. Oncologist, 2016, 21(7), 855-860.
[http://dx.doi.org/10.1634/theoncologist.2015-0248] [PMID: 27151652]
[31]
Castel, P.; Toska, E.; Engelman, J.A.; Scaltriti, M. The present and future of PI3K inhibitors for cancer therapy. Nat. Can., 2021, 2(6), 587-597.
[http://dx.doi.org/10.1038/s43018-021-00218-4] [PMID: 35118422]
[32]
Wu, Y-L.; Cheng, Y.; Zhou, X.; Lee, K.H.; Nakagawa, K.; Niho, S.; Tsuji, F.; Linke, R.; Rosell, R.; Corral, J.; Migliorino, M.R.; Pluzanski, A.; Sbar, E.I.; Wang, T.; White, J.L.; Nadanaciva, S.; Sandin, R.; Mok, T.S. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small- cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncol., 2017, 18(11), 1454-1466.
[http://dx.doi.org/10.1016/S1470-2045(17)30608-3]
[33]
Liu, D.; Weintraub, M.A.; Garcia, C.; Goncalves, M.D.; Sisk, A.E.; Casas, A.; Harding, J.J.; Harnicar, S.; Drilon, A.; Jhaveri, K.; Flory, J.H. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. Cancer Med., 2022, 11(8), 1796-1804.
[http://dx.doi.org/10.1002/cam4.4579] [PMID: 35212193]
[34]
Fiascarelli, A.; Merlino, G.; Capano, S.; Talucci, S.; Bisignano, D.; Bressan, A.; Bellarosa, D.; Carrisi, C.; Paoli, A.; Bigioni, M.; Tunici, P.; Irrissuto, C.; Salerno, M.; Arribas, J.; de Stanchina, E.; Scaltriti, M.; Binaschi, M. Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer. Breast Cancer Res. Treat., 2023, 199(1), 13-23.
[http://dx.doi.org/10.1007/s10549-023-06895-2] [PMID: 36913051]
[35]
Graupera, M.; Potente, M. Regulation of angiogenesis by PI3K signaling networks. Exp. Cell Res., 2013, 319(9), 1348-1355.
[http://dx.doi.org/10.1016/j.yexcr.2013.02.021] [PMID: 23500680]
[36]
Hirsch, E.; Ciraolo, E.; Franco, I.; Ghigo, A.; Martini, M. PI3K in cancer–stroma interactions: Bad in seed and ugly in soil. Oncogene, 2014, 33(24), 3083-3090.
[http://dx.doi.org/10.1038/onc.2013.265] [PMID: 23893246]
[37]
Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov., 2009, 8(8), 627-644.
[http://dx.doi.org/10.1038/nrd2926] [PMID: 19644473]
[38]
Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet., 2006, 7(8), 606-619.
[http://dx.doi.org/10.1038/nrg1879] [PMID: 16847462]

Rights & Permissions Print Cite
Article Metrics
26
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy